Start Up Spotlight: SurgiMab Aims For First-In-Market Tumor-Detecting Fluorescent Probe For FGS
Executive Summary
SurgiMab is aiming for its lead product, SGM-101, to be the first tumor-targeted fluorescent probe to be marketed for fluorescence-guided surgery (FGS). Based in Montpellier, France, the company has initiated a Phase III trial to assess the clinical benefit of using FGS with SGM-101 as the intraoperative imaging agent to identify cancer lesions during colorectal surgery.